127 related articles for article (PubMed ID: 10448272)
1. Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis.
Engblom P; Pulkkinen JO; Rantanen V; Hirvonen H; Kulmala J; Grènman R; Grènman S
Eur J Cancer; 1999 Feb; 35(2):284-8. PubMed ID: 10448272
[TBL] [Abstract][Full Text] [Related]
2. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.
Fjällskog ML; Frii L; Bergh J
Eur J Cancer; 1994; 30A(5):687-90. PubMed ID: 7915908
[TBL] [Abstract][Full Text] [Related]
4. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines.
Liebmann J; Cook JA; Lipschultz C; Teague D; Fisher J; Mitchell JB
Cancer Chemother Pharmacol; 1994; 33(4):331-9. PubMed ID: 7904231
[TBL] [Abstract][Full Text] [Related]
5. Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro.
Csóka K; Dhar S; Fridborg H; Larsson R; Nygren P
Cancer; 1997 Mar; 79(6):1225-33. PubMed ID: 9070502
[TBL] [Abstract][Full Text] [Related]
6. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
Decorti G; Bartoli Klugmann F; Candussio L; Baldini L
Anticancer Res; 1996; 16(1):317-20. PubMed ID: 8615628
[TBL] [Abstract][Full Text] [Related]
7. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
Szebeni J; Muggia FM; Alving CR
J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
[TBL] [Abstract][Full Text] [Related]
8. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
9. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Bardelmeijer HA; Ouwehand M; Malingré MM; Schellens J; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
[TBL] [Abstract][Full Text] [Related]
10. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
Rischin D; Webster LK; Millward MJ; Linahan BM; Toner GC; Woollett AM; Morton CG; Bishop JF
J Natl Cancer Inst; 1996 Sep; 88(18):1297-301. PubMed ID: 8797769
[TBL] [Abstract][Full Text] [Related]
11. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
de Vos AI; Nooter K; Verweij J; Loos WJ; Brouwer E; de Bruijn P; Ruijgrok EJ; van der Burg ME; Stoter G; Sparreboom A
Ann Oncol; 1997 Nov; 8(11):1145-50. PubMed ID: 9426335
[TBL] [Abstract][Full Text] [Related]
12. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
[TBL] [Abstract][Full Text] [Related]
13. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
14. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20.
Weiszhár Z; Czúcz J; Révész C; Rosivall L; Szebeni J; Rozsnyay Z
Eur J Pharm Sci; 2012 Mar; 45(4):492-8. PubMed ID: 21963457
[TBL] [Abstract][Full Text] [Related]
15. [Study for modifying activity of solvents on antitumor activity of paclitaxel].
Fujimoto S
Gan To Kagaku Ryoho; 1994 Apr; 21(5):665-70. PubMed ID: 7908793
[TBL] [Abstract][Full Text] [Related]
16. Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): role of the solvent Cremophor EL/ethanol.
Cordes N; Plasswilm L
Anticancer Res; 1998; 18(3A):1851-7. PubMed ID: 9673415
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of fractionated paclitaxel (Taxol) administration in vitro.
Plasswilm L; Cordes N; Fietkau R; Sauer R
Strahlenther Onkol; 1998 Jan; 174(1):37-42. PubMed ID: 9463563
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines.
Liebmann JE; Cook JA; Lipschultz C; Teague D; Fisher J; Mitchell JB
Br J Cancer; 1993 Dec; 68(6):1104-9. PubMed ID: 7903152
[TBL] [Abstract][Full Text] [Related]
19. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro.
Raitanen M; Rantanen V; Kulmala J; Helenius H; Grénman R; Grénman S
Int J Cancer; 2002 Jul; 100(2):238-43. PubMed ID: 12115575
[TBL] [Abstract][Full Text] [Related]
20. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
Nygren P; Csoka K; Jonsson B; Fridborg H; Bergh J; Hagberg H; Glimelius B; Brodin O; Tholander B; Kreuger A
Br J Cancer; 1995 Mar; 71(3):478-81. PubMed ID: 7880727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
